APPENDIX B 
Non-Technical Abstract 
Nontechnical description of protocol 
We plan to deliver genetic information ("DNA") to the tumor cells of melanoma patients. Because 
it is difficult to deliver DNA directly to cells, we plan to use replication defective viruses 
("vectors") that efficiently deliver the DNA to living cells. These vectors cause the patients tumor 
cells to produce an important protein called gamma interferon (y-IFN). y-IFN is an important 
protein because it causes the tumor cell to be brought to the attention of the patient's immune 
system. It is hoped that the resultant expression of y-IFN from the tumor cells will dramatically 
improve immune responses that combat human cancer. 
Tumor cells from human melanomas removed surgically from the patient will be grown in the 
laboratory under sterile conditions. The cell culture will then be placed in contact with the vector 
that contains the DNA coding for y-IFN . After a process which removes tumor cells which have 
not taken up the y-IFN DNA, the cells will be tested for sterility, irradiated with X-rays so that 
they can no longer grow, and the tumor cells expressing y-IFN will be re-injected into the same 
patient. The study will determine if the approach is safe, if the patient's clinical condition is 
improved, and whether immune responses against the tumor have been improved. 
Recombinant DNA Research, Volume 17 
[6111 
